DATROWAY Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic TNBC Who Are Not Candidates ...
Add Yahoo as a preferred source to see more of our stories on Google. Eligible patients had received between one and four previous lines of chemotherapy. Credit: Thomas Andreas via Shutterstock.
DATROWAY demonstrated statistically significant and clinically meaningful improvement in overall survival as 1st-line therapy for patients with metastatic triple-negative breast cancer for whom ...
The FDA accepted a supplemental biologics license application and granted priority review for Datroway for adults unresectable or metastatic triple-negative breast cancer who are not candidates for PD ...
A sign is pictured during the unveiling of AstraZeneca's new manufacturing facility, to be operational in the coming months with an initial focus on T-cell therapies, in Rockville, Maryland, U.S., May ...
Daiichi Sankyo and AstraZeneca’s DATROWAY also demonstrated a highly statistically significant and clinically meaningful 43% reduction in patients’ risk of disease progression or death DATROWAY is the ...
How Does Datroway Work for Breast Cancer? Datroway is a type of medicine known as an antibody drug conjugate (ADC). The ADC is designed to deliver medicine directly to the cancer cells and is made up ...
Japanese drugmaker Daiichi Sankyo has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labor and Welfare (MHLW) for Datroway (datopotamab deruxtecan) for the ...
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the TROPION-Breast02 Phase III trial showed DATROWAY ® (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically ...
AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for DATROWAY®(datopotamab deruxtecan-dlnk) has been accepted and granted Priority Review in the US for the treatment ...
Approximately 70% of metastatic triple-negative breast cancer patients are ineligible for immunotherapy, creating an unmet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results